Director/PDMR Shareholding

RNS Number : 4873F

Allergy Therapeutics PLC

25 April 2014

 



25 April 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Grant of Options

Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP') on 24 April 2014 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors, Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:

Director	Number of provisional shares awarded	Date of distribution	Total provisional shares held under LTIPs
Manuel Llobet	845,000	24 April 2014	3,190,000
Ian Postlethwaite	422,500	24 April 2014	1,595,000

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of three years. The new Long Term Incentive Plan was adopted by the Board on 20 March 2013.

-Ends-

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP	[phone]
James Steel / Clare Terlouw
FTI Consulting	[phone]
Simon Conway/ Mo Noonan / Victoria Foster-Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

RDSBLGDSUUDBGSS